Open AccessPredicting long‐term clinical stability in amyloid‐positive subjects by FDG ‐ PET
Author(s) -
Iaccarino Leonardo,
Sala Arianna,
Perani Daniela
Publication year - 2019
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.782
Subject(s) - neuropathology , medicine , neurodegeneration , biomarker , clinical trial , pet imaging , oncology , amyloid (mycology) , disease , alzheimer's disease , positron emission tomography , pathology , nuclear medicine , biochemistry , chemistry
Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials. To test the predictive values in clinical progression of neuropathology change (amyloid‐ PET ) or brain metabolism as neurodegeneration biomarker ([18F]F DG ‐ PET ), we evaluated data from N = 268 healthy controls and N = 519 mild cognitive impairment subjects. Despite being a significant risk factor, amyloid positivity was not associated with clinical progression in the majority (≥60%) of subjects. Notably, a negative [18F]F DG ‐ PET scan at baseline strongly predicted clinical stability with high negative predictive values (>0.80) for both groups. We suggest [18F]F DG ‐ PET brain metabolism or other neurodegeneration measures should be coupled to amyloid‐ PET to exclude clinically stable individuals from clinical trials.